Dr. Santosh M. Nair, MD

Dr. Nair practices at Mid-Florida Hematology & Oncology Centers PA in Orange City, Florida.

Dr. Nair's NPI, 1982653713, was assigned on May 9, 2006. Dr. Nair holds Florida license ME80497.

Dr. Nair's primary practice is Mid-Florida Hematology & Oncology Centers PA, at 2776 Enterprise Rd, Orange City, FL 32763 in Volusia County. The practice phone is (386) 774-1223.

Dr. Nair's primary practice is Mid-Florida Hematology & Oncology Centers PA in Orange City, Florida. Dr. Nair is also affiliated with AdventHealth Fish Memorial. The medical group on file is Mid Florida Cancer Centers. Dmand AI also links Dr. Nair to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nair practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nair's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Nair is licensed in Florida.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer, lymphoma and multiple myeloma among the conditions Dr. Nair treats.

CMS data shows 78,896 Medicare services from Dr. Nair across 48 procedure codes in 2024, for 418 Medicare patients. Medicare paid $804,462 for them.

CMS counts 418 Medicare patients who saw Dr. Nair in 2024. The largest group is 75 to 84, with 169 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nair's median patient age at 72, with 64% women.

In 2024, Dr. Nair wrote 2,296 Medicare Part D claims for 292 patients. 64% of them were for generic drugs. CMS names the drug for 1,884 of them, across 61 drugs with 11 or more claims each, at $4,383,924 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Nair for performance year 2024, reported as part of a group. Dr. Nair accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Nair, published from 2020 to 2024. Dr. Nair has published most often in Blood Adv. Dr. Nair's most frequent co-authors are Abdullah Kutlar, MD, Darla Kaye Liles, MD and Deepa Manwani, MD.

Dmand AI links Dr. Nair to 10 clinical trials, 4 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Small Cell. G1 Therapeutics, Inc. sponsors the most, 3. Open Payments lists research payments to Dr. Nair that name 3 trials.

CMS Open Payments shows 4 general payments to Dr. Nair from 2 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Daiichi Sankyo Inc. paid the most, $44. It also lists 7 research payments totaling $11,748 in 2024, naming 3 clinical trials.

Dr. Nair is in network with 20 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 12. Check the plan with the practice before a visit.